CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc.’s reporting persons report shared voting and dispositive power over 163,982 common shares, representing 9.9% of the class. The joint filers are Ascent Partners Fund LLC, Ascent Partners LLC, Dominion Capital LLC, Dominion Capital GP LLC, Eagle Claw Corp., Masada Group Holdings LLC, Mikhail Gurevich, Gennadiy Gurevich and Alon Brenner. Mikhail Gurevich is Eagle Claw’s Chief Investment Officer, Gennadiy Gurevich its President, and Alon Brenner manages Masada Group Holdings LLC. The reported ownership includes shares associated with Ascent’s Directed Stock Purchase Agreement, subject to an aggregate beneficial-ownership cap of 9.99%; the calculation references up to 163,982 shares that may be issued under the agreement. CDT’s reported percentage uses 1,477,489 shares outstanding after its 1-for-25 reverse stock split, effective September 28, 2026.
CDT Equity Inc. seeks approval to issue shares under senior secured convertible notes and warrants issued to J.J. Astor & Co.; the October note reset the existing note’s floor price lower, increasing potential conversion shares. It also seeks reverse-split authority. The virtual meeting is November 12, 2026; the board recommends “FOR” all proposals.
The October note has $6.75 million principal. Its first tranche covers $4.05 million; CDT received $3 million before fees and $2,869,850 net. A $2 million second tranche depends on conditions including stockholder approval and a closing bid of at least $3.00 for five trading days before closing. The note is payable in 24 weekly $168,750 installments beginning October 14, 2026, subject to increase upon second-tranche funding. Its conversion price uses a $0.18354 floor and a 4.99% beneficial-ownership cap, which the lender may raise to 9.99% or 19.99% by written notice.
At the Record Date closing price, up to 71,435,769 conversion shares could be issuable before applying the note formula or ownership cap; full cash exercise of warrants could issue 373,220 shares. Proposed reverse splits range from 1-for-2 to 1-for-100, with aggregate splits capped at 1-for-1,000. The board may choose whether and at what ratio to proceed, or abandon amendments before effectiveness; authorized common shares would remain unchanged.
CDT Equity Inc. reported two share acquisitions tied to severance and a service fee. On October 23, 2026, at the issuer’s request, $65,000 of Dr. Regan’s remaining severance was converted into 499,616 common shares at $0.1301 per share; his direct holdings then totaled 499,618 shares. On October 22, 2026, CDT issued 1,347,616 shares to Manoira Corporation in full satisfaction of a $195,000 one-time fee under an Evaluation Agreement, at $0.1447 per share; Manoira then held 1,347,619 shares. Corvus Capital Ltd. separately held 217,461 shares of record. Corvus owns 87.0% of Manoira; Dr. Regan is Corvus’s CEO and sole shareholder, and both disclaim beneficial ownership except to the extent of their pecuniary interests. No Rule 10b5-1 plan is reported.
CDT Equity Inc. reports that Corvus Capital Ltd., a 10% owner, exercised all of its pre-funded warrants cashlessly on August 28, 2026, after stockholder approval for issuance of the underlying common stock, receiving 543,683 shares. The exercise price was $0.0001 per share. The transaction table lists a 29-share sale, while a related footnote says the issuer withheld 290 shares to pay the exercise price.
Following the August 28 transactions, Corvus reported 569,322 common shares held indirectly. The amendment reflects a 1-for-10 reverse stock split effected July 20, 2026, adds Corvus as a filer because it was a 10% owner when the original Form 4 was filed, and updates information about Manoira Corporation. Dr. Andrew Regan, CDT Equity's Chief Executive Officer and Corvus's sole shareholder, may be deemed to beneficially own shares and warrants held by Corvus and Manoira; he and Corvus disclaim such beneficial ownership except to the extent of their respective pecuniary interests.
CDT Equity Inc. issued Manoira Corporation 1,347,616 common shares on October 22, 2026, at $0.1447 per share in full satisfaction of a one-time $195,000 fee under an Evaluation Agreement to assess clinical-stage compounds for animal-health applications. At CDT’s request, $65,000 of Andrew Regan’s severance was converted into 499,616 common shares on October 23, 2026, at $0.1301 per share. Regan became eligible for $300,000 in severance in connection with his resignation as CDT’s CEO and a director, effective August 31, 2026.
CDT had 9,322,805 common shares outstanding as of October 23, 2026. Reported beneficial ownership as of October 26 lists Regan at 2,064,698 shares, Corvus Capital Ltd. at 1,565,080 and Manoira at 1,347,619. Corvus owns 87.0% of Manoira; Regan is Corvus’s CEO and sole shareholder. Anton Connolly is identified as Manoira’s COO and a director.
CDT Equity Inc. (CDT) has a reported direct ownership position of 1,347,619 shares of common stock held by Manoira Corp, identified as a ten percent owner. The position is dated October 22, 2026; the entry records a holding rather than a reported purchase or sale.
CDT Equity Inc. (CDT) entered an Evaluation Agreement with Manoira Corporation on October 22, 2026. Manoira will assess whether CDT’s clinical-stage compounds AZD1656 and AZD5904 can improve Manoira’s animal-health products. CDT issued Manoira 1,347,616 shares at $0.1447 per share to settle the $195,000 total payment due to Manoira.
Manoira will evaluate the assets in combination with its products for potential effects on efficacy, safety, formulation, or other commercially relevant characteristics. If the evaluation is successful, CDT and Manoira intend to enter licensing and commercialization discussions covering sales of resulting products following launch. Manoira was preparing to launch its first animal-health product range in the first quarter of 2027.
CDT also reported issuing 397,374 shares to a service provider for consulting services, 437,779 shares to Sarborg Limited under a securities purchase agreement dated August 31, 2026, and 499,616 shares to former Chief Executive Officer and former board member Dr. Andrew Regan in lieu of $65,000 in severance compensation. The company stated that these share issuances were unregistered and made in reliance on exemptions under Section 4(a)(2) and/or Rule 506 of Regulation D. Dr. Regan is Manoira’s sole director and will not receive consideration from the agreement.
CDT Equity Inc. is seeking approval to issue common shares under senior secured convertible notes and warrants issued to J.J. Astor & Co., and authorization for reverse stock splits. At the virtual special meeting on November 12, 2026, the board recommends “FOR” all three proposals. Full conversion and warrant exercise could result in issuance of 20% or more of shares outstanding as of June 11, 2026; full cash exercise of the warrants would issue 373,220 shares.
The October Note has a $6,750,000 principal amount. Its first tranche covered $4,050,000 of principal and provided $3,000,000 before fees, with $2,869,850 in net proceeds. A second $2,000,000 funding tranche, tied to the remaining $2,700,000 of principal, is subject to conditions on or before December 31, 2026. The note matures March 24, 2027, with 24 weekly installments of $168,750 beginning October 14, 2026, subject to increase if the second tranche is funded.
The proposed split may be 1-for-2 to 1-for-100 per amendment, with aggregate reverse splits capped at 1-for-1,000. After approval, the board may select the ratio or abandon the amendments; the authorized common share count would remain unchanged. A majority of votes cast is required on each proposal.
CDT Equity Inc. is supplementing its resale prospectus for 673,023 shares of common stock offered by selling stockholders. CDT is not selling securities and will receive no proceeds from their resales; selling stockholders may sell any, all or none.
On October 6, 2026, CDT issued a senior secured convertible note with $6,750,000 original principal; it provides for $5,000,000 of funding in two tranches. CDT received $3,000,000 in the first tranche against $4,050,000 of principal before fees; net proceeds were $2,869,850. A further $2,000,000 for the remaining $2,700,000 principal is conditional, including on resale-registration effectiveness and stockholder approval. Repayment is in 24 weekly installments of $168,750 starting October 14, 2026; the note matures March 24, 2027.
The note converts at the greater of 70% of the lowest closing price during the preceding 20 consecutive trading days or a $0.18354 floor, subject to resets; a 4.99% ownership cap may be raised to 9.99% or 19.99% by written notice. The lender received warrants for 225,000 shares at an exercise price of $0.9177 per share. Eighty percent of net proceeds from ATM sales on or after October 6, 2026, must go first to this note.
CDT Equity Inc. (CDT) issued J.J. Astor & Co. a senior secured convertible note with a $6.75 million principal amount, funded in two tranches. CDT received $3 million before closing fees from the first tranche, with net proceeds of $2,869,850. A second $2 million tranche, associated with $2.7 million of principal, is subject to conditions on or before December 31, 2026, including an effective resale registration statement, stockholder approval, no event of default and a closing bid of at least $3.00 for the five trading days before the second closing.
The note matures March 24, 2027 and is payable in 24 weekly installments of $168,750, commencing October 14, 2026, subject to increase upon second-tranche funding. Astor received warrants for 225,000 shares at $0.9177 per share, exercisable immediately and expiring five years after issuance. The conversion price is the greater of 70% of the lowest closing price over the preceding 20 consecutive trading days or $0.18354, subject to resets. Eighty percent of net proceeds from ATM sales on or after October 6, 2026 must first go toward this note; specified proceeds from other financings are also subject to prepayment requirements. CDT agreed to convene a stockholder meeting by November 13, 2026 to seek approval for conversion and warrant shares to the extent required by Nasdaq rules.